FDA Adverse Event Injury Summary report: N

TAXUS® LIBERTÉ®

MDR report key: 2862953 · Received December 10, 2012

Report

Report Number
2134265-2012-07458
Event Type
Injury
Date Received
December 10, 2012
Date of Event
November 9, 2012
Report Date
November 9, 2012
Manufacturer
BOSTON SCIENTIFIC - GALWAY
Product Code
NIQ
PMA / PMN Number
P060008
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
IL, US
Reporter Occupation
PHYSICIAN

Narratives

Additional Manufacturer Narrative · 1

DEVICE IS COMBINATION PRODUCT. DEVICE EVALUATED BY MANUFACTURER: DEVICE EVALUATED BY MFR: THE DEVICE WAS NOT RETURNED FOR EVALUATION; THEREFORE A FAILURE ANALYSIS OF THE COMPLAINT DEVICE COULD NOT BE COMPLETED. THE MANUFACTURING BATCH RECORD REVIEW CONFIRMED THAT THE DEVICE MET ALL MATERIAL, ASSEMBLY AND PERFORMANCE SPECIFICATIONS. THE ROOT CAUSE IS ANTICIPATED PROCEDURAL COMPLICATIONS AS THIS EVENT IS A KNOWN PHYSIOLOGICAL EFFECT OF THE PROCEDURE AND IS NOTED WITHIN THE DFU. (B)(4).

Description of Event or Problem · 1

IT WAS REPORTED THAT FOLLOWING A STENTING TREATMENT PROCEDURE, IN-STENT RESTENOSIS OCCURRED. THE PROCEDURE TREATED THE 75% STENOSED TARGET LESION LOCATED IN THE MILDLY CALCIFIED AND MILDLY TORTUOUS LEFT ANTERIOR DESCENDING ARTERY. USING A DIRECT STENTING TECHNIQUE, A 3.0X16MM TAXUS LIBERTE STENT WAS ADVANCED AND DEPLOYED AT 14 ATMS FOR 90 SECONDS RESULTING IN 0% RESIDUAL STENOSIS. NO POST DILATION WAS PERFORMED. IN 11/2012, THE PATIENT PRESENTED WITH SUBSTERNAL CHEST PAIN AND IN-STENT RESTENOSIS WAS REVEALED WITH TIMI FLOW 0. TREATMENT CONSISTED OF PRE-DILATION WITH AN UNSPECIFIED BALLOON INFLATED TO 15 ATMS FOR 10 SECONDS AND THE PLACEMENT OF A 3.0X16MM PROMUS ELEMENT PLUS STENT DEPLOYED AT 22 ATMS FOR 45 SECONDS WITH EXCELLENT RESULT AND 0% RESIDUAL STENOSIS AND TIMI 3 FLOW. NO FURTHER PATIENT COMPLICATIONS WERE REPORTED.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1 TAXUS® LIBERTÉ® CORONARY DRUG-ELUTING STENT NIQ BOSTON SCIENTIFIC - GALWAY H7493893616300 7234686

Patients

Seq Age Sex Outcome Treatment
1 74 YR Required Intervention